TABLE 2.

Clinical characteristics of study cohort at relapse.

Clinical characteristics	At relapse % (N)
Remission status at relapse
CR1	90% (28)
IF	10% (3)
Duration of IF or CR1 at relapse
≤18 months	48% (15)
18–36 months	23% (7)
>36 months	29% (9)
Site of relapse
BM	62% (19)
BM + other sites:	16% (5)
BM + CNS	13% (4)
BM + Testis	3% (1)
Isolated extra‐medullary:	23% (7)
CNS	16% (5)
Testis	6% (2)
Risk stratification at relapse
Low risk (LR)	6% (2)
Intermediate risk (IR)	23% (7)
High risk (HR)	71% (22)
Salvage therapy received
First‐salvage chemotherapy	55% (17)
Second‐salvage therapy	45% (14)
Hematopoietic stem cell transplantation (HSCT)	42% (13)